Sinovac Biotech (SVA) said Sunday it has been notified by Nasdaq that it has failed to comply with a listing rule requiring the timely filing of a Form 6-K containing an interim balance sheet and income statement at the end of Q2 2025.
The company said it is evaluating the notification and intends to present its plan at a scheduled hearing on Jan. 8 with the objective of maintaining its Nasdaq listing.